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Abstract
Background HNF1B gene mutations are an important cause of bilateral (cystic) dysplasia in children, complicated by chronic
renal insufficiency. The clinical variability, the absence of genotype-phenotype correlations, and limited long-term data render
counseling of affected families difficult.
Methods Longitudinal data of 62 children probands with genetically proven HNF1B nephropathy was obtained in a multicenter
approach. Genetic family cascade screening was performed in 30/62 cases.
Results Eighty-seven percent of patients had bilateral dysplasia, 74% visible bilateral, and 16% unilateral renal cysts at the end of
observation. Cyst development was non-progressive in 72% with a mean glomerular filtration rate (GFR) loss of − 0.33 ml/min/
1.73m2 per year (± 8.9). In patients with an increase in cyst number, the annual GFR reduction was − 2.8 ml/min/1.73m2 (± 13.2),
in the total cohort − 1.0 ml/min/1.73m2 (±10.3). A subset ofHNF1B patients differs from this group and develops end stage renal
disease (ESRD) at very early ages < 2 years. Hyperuricemia (37%) was a frequent finding at young age (median 1 year), whereas
hypomagnesemia (24%), elevated liver enzymes (21%), and hyperglycemia (8%) showed an increased incidence in the teenaged
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child. Genetic analysis revealed no genotype-phenotype correlations but a significant parent-of-origin effect with a preponder-
ance of 81% of maternal inheritance in dominant cases.
Conclusions In most children, HNF1B nephropathy has a non-progressive course of cyst development and a slow-progressive
course of kidney function. A subgroup of patients developed ESRD at very young age < 2 years requiring special medical
attention. The parent-of-origin effect suggests an influence of epigenetic modifiers in HNF1B disease.
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Introduction
Congenital anomalies of the kidneys including renal dys-
plasia are a common cause of renal failure in children [1].
Diagnosis of kidney dysplasia in clinical routine is based
on ultrasonography, showing an echo-bright kidney with or
without cysts and poor corticomedullary differentiation
[2]. Renal histology defines kidney dysplasia by showing
incompletely branched ducts surrounded by undifferentiat-
ed and metaplastic stroma [3, 4]. In a significant number of
cases, gene mutations in HNF1B on chromosome 17q21.3
have been identified as underlying cause. HNF1B encodes
for hepatocyte nuclear factor-1ß (HNF-1ß), a transcription
factor that is expressed early in embryonic development.
HNF-1ß acts as a homo- or heterodimer with HNF-1α and
plays a key role for tissue-specific regulations of gene ex-
pression in various organs such as the kidneys, liver, bili-
ary ducts, pancreas, and the urogenital tract [5, 6]. First,
HNF1B gene mutations were identified in patients with
maturity onset diabetes of the young (MODY 5) in 1997
[7]. Today, HNF1B disease is recognized to represent an
autosomal dominant syndromal disorder comprising renal
cystic disease, diabetes mellitus, elevated liver enzymes,
hyperur icemia, and pancreat ic and geni ta l t ract
malformations (MIM 137920; renal cysts and diabetes syn-
drome, RCAD) [8]. Some patients with HNF1B mutations
show hypomagnesemia caused by hypermagnesiuria [9]
which is in part due to the control of FXYD2 expression
by HNF-1ß in the distal tubule [10]. HNF1B mutations are
also identified in pediatric patients with isolated renal dys-
plasia with cysts [11–14]. The nephropathy in these cases
is part of the autosomal dominant tubulointerstitial kidney
disease spectrum ADTKD [15], formerly known as med-
ullary cystic kidney disease (MCKD). Next to HNF1B
three other genes (MUC1, UMOD, and REN) with shared
clinical features have been assigned to this prototypic
group of nephropathies. We here focussed on genetically
proven HNF1B nephropathy in children and sought to de-
fine the longitudinal clinical course, the progression of
renal disease, and the manifestation of extrarenal symp-
toms. For this purpose, we initiated a national clinical reg-
istry encompassing a pediatric cohort of young age.
Additional data from the Czech Republic and Poland were
included in a collaborative approach.
Material and methods
Patients
Sixty-two children probands (39 males; aged 0–18 years)
treated at one of 11 pediatric nephrology units in Germany,
the Czech Republic, and Poland, were recruited, and annual
data were collected from a total of 323 questionnaires (median
follow-up 4 years; range 1 month–19 years, Suppl. Material
1a, b). Clinical and laboratory data as well as repeated renal
ultrasound data were collected as described below. All patients
entered in the study had primarily been seen by expert pedi-
atric nephrologists. A renal phenotype with cystic or non-
cystic kidney dysplasia and/or tubulointerstitial kidney dis-
ease (TKD) led to the initiation of HNF1B mutational analy-
sis. Inclusion criterion of the study was confirmed HNF1B
nephropathy with provenmutation inHNF1B. For this reason,
the HNF1B score published by Faguer et al. [16] to identify
patients suitable for HNF1Bmutation testing was not applica-
ble in the present study.
Mutation analysis
Genomic deoxyribonucleic acid (DNA) was extracted from
peripheral blood. Exons 1–9 of HNF1B, including intron-
exon boundaries, were amplified by polymerase chain reac-
tion (PCR) and subjected to exon-specific next-generation se-
quencing (NGS) and Sanger sequencing. The result was com-
pared to the published sequence NM_000458.2. Multiplex
ligation-dependent probe amplification (MLPA) analysis was
performed to determine the presence of copy number varia-
tions, deletions, or duplications (SALSA MLPA P241 probe
mix;MRC-Holland, Amsterdam, Netherlands) [17], including
GCK, HNF1A, HNF1B, and HNF4A.
Renal ultrasound
Repeated renal ultrasound examinations were performed an-
nually at each center. Renal dysplasia was defined as poor
corticomedullary differentiation, echo-bright kidneys, or both
[2]. For medical and ethical reasons, affected children are
generally not biopsied which might be a limitation of the
study. Renal cysts were categorized by number (n ≤ 5 or n >
5), and a cyst score was applied to define an increase in cyst
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number over time (no cysts, score 0; ≤ 5 cysts, score 1; > 5
cysts, score 2). Progressive disease was defined as cyst pro-
gression in at least one kidney.
Clinical and laboratory data
Baseline and follow-up data of age, height, onset of nephrop-
athy, ESRD, hypomagnesemia, hyperglycemia, hyperurice-
mia, elevated liver enzyme activity, exocrine pancreas insuf-
ficiency, and anomalies of the genital tract were documented
following external physical and ultrasound examination and
laboratory assessment. Age-dependent reference limits were
applied [18–20]. Hypomagnesemia was defined as repeated
serum magnesium concentrations lower than 0.65 mmol/l.
The estimated glomerular filtration rate (eGFR) was calculat-
ed from serum creatinine and body height according to the
Schwartz formula [21]. The CKD Work Group’s KDIGO
guidelines were used to define chronic kidney disease
(CKD) stages I–V [22].
Family histories were documented including genetic results
and reported HNF1B-related symptoms as provided by the
cooperating centers.
Statistical analysis
Data are given as the median and/or mean with standard de-
viation (SD). Statistical analysis was assessed using Student’s
t test. Statistical significance was defined as p ≤ 0.05.
Results
Genetics
HNF1B whole gene deletions (exons 1–9) were detected in
33/62 patients (53%), missense mutations in 11 (18%), non-
sense (stop) mutations in 7 (11%), and splice mutations/gross
insertions in 11 (18%) (Table 1). Parental DNA of 28 families
(30 patients) was subjected to cascade screening, and parental
transmission of HNF1B gene mutations was observed in 16/
28 families with maternal transmission in 13/16 (81%) and
paternal in 3/16 (19%). 11/16 (71%) parental mutation carriers
exhibited symptoms related to HNF1B. Four parental muta-
tion carriers had no documented clinical symptoms. We have
no information whether a systematic screening in these four
individuals was performed which is a limitation of this study.
In one parental mutation carrier with proven genetic result, no
clinical information was available. De novo mutations were
detected in 12/30 patients (40%). Among these, 10/12 (83%)
constitute complete gene deletions, 1/12 a missense, and 1/12
a stop mutation. Three missense mutations (Asp82Asn,
Val61Gly, and Gly76Cys) are annotated in the gnomAD da-
tabase with allele frequencies of approximately 1–2:1000 in
large populations of different ethnic origins (http://gnomad.
broadinstitute.org); however, the phenotype of the study
patient affected by Asp82Asn shows typical HNF1B disease,
and both Val61Gly and Gly76Cys have been reported in
different HNF1B studies in patients with HNF1B disease
(http://www.hgmd.cf.ac.uk). As CAKUT is as frequent as
1% in the general population, these missense mutations most
likely represent hypomorphic variants associated withHNF1B
disease in conjunction with other genetic or environmental
events [12, 23]. The same holds true for patient 10, offspring
of consanguineous union and affected by a homozygous
Arg232Cys mutation, and a full-blown picture of HNF1B
disease.
There were no statistically significant differences in renal
function or phenotypes among carriers of different HNF1B
mutation types (p > 0.05 between all groups; Table 2 and
Suppl. Table 1). The mean GFR at the end of observation in
the group of patients with deletions was 106.8 ml/min/1.73m2
(mean age 12.0 years, median age 8.0 years) vs. 98.0 ml/min/
1.73m2 (mean age 8.4 years, median age 7.0 years) in the
group with non-deletion mutations (p > 0.05).
Renal phenotype
Prenatal dysplasia was documented for 32/62 patients (52%);
(no data n = 30). At the end of follow-up, ultrasound revealed
bilateral dysplasia in 54 patients (87%), unilateral dysplasia in
3, unilateral dysplasia with contralateral agenesis in 4, and no
documented dysplasia in 1 (Fig. 1a).
Bilateral renal cysts—at the end of follow-up—were pres-
ent in 46/62 patients (74%), unilateral cysts in 10 (16%), and
no cysts in 6 (10%). Most patients experienced no statistically
significant increase (p > 0.05) in the number of renal cysts at a
median follow-up of 4 years (mean 5.2 years; range 1 month–
19 years). Of the total cohort with at least two renal ultrasound
examinations, no increase was documented in 34/47 patients
(72%); and an increase in 13/47 patients (28%): in 4 patients,
cysts were observed for the first time during the course of the
study; and in nine patients, the cyst score increased from 1 to
2; Fig. 1b).
At the end of follow-up, bilateral dysplasia with cysts was
found in 46/62 patients (74%), and unilateral dysplasia with
cysts and contralateral kidney agenesis was found in two.
Unilateral cystic dysplasia with a normal contralateral kidney
was documented for eight patients (13%). From the remaining
six patients, five showed renal dysplasia but no cysts.
Renal function
Kidney function exhibited wide interindividual variability. At
the end of follow-up, ESRD was documented in 5/62 (8%)
with a median age of 15 months (range 3 months–6 years); all
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Table 1 Patient cohort
Patient Gender HNF1B mutation Classification Renal
sonography
Extrarenal
manifestations
CKD Family genetics Family history
1 m c.244G>A; p.Asp82Asn (het)§ Missense D, C U 1 ND
2 m c.182 T >G; p.Val61Gly (het)§ Missense D, c 1 ND
3 m DEL (het) Deletion D, L 1 ND
4 m DEL (het) Deletion D, c U 5 ND
5 f c.182 T >G; p.Val61Gly (het) § Missense D, C 5 ND
6 m DEL (het) Deletion D, C L 1 ND
7 m c.526C > T; p.Gln176* (het) Stop D, C 2 Paternal No anomalies
8 f DEL (het) Deletion D, C U, L 2 Maternal CRI; renal cysts
9 m c.544 + 3_544 + 6delAAGT (het) Splice D, C U, L 5 Maternal CRI; renal cysts;
uterus bicornis;
gestational
diabetes
10 m c.694C > T; p.Arg232Cys (hom)§§ Missense d*, c U, L, M 1 ND
11 m DEL (het) Deletion D, C 2 Maternal GFR normal;
renal cysts
12 m c.226G> T; p.Gly76Cys (het)§ Missense D, C U, L 1 ND
13 m DEL (het) Deletion D, C 2 ND
14 f c.182 T >G; p.Val61Gly (het)§ Missense d, c 2 ND
15 m Duplication exon 5 (het) Gross insertion D, C 2 Paternal No anomalies
16 f Duplication exon 5 (het) Gross insertion D, C 1 Paternal No anomalies
17 f c.544C > T; pGln182* (het) Stop D, C 1 Maternal CRI; unilateral
kidney agenesis
18 f c.544 + 1G >A (het) Splice D, C 5 Paternal CRI
19 f DEL (het) Deletion D, C 1 ND
20 f c.544 + 3_544 + 6delAAGT (het) Splice D, C U, M 2 ND
21 m DEL (het) Deletion D, C M 3 De novo
22 m c.512G>A; p.Trp171* (het) Stop D, C 2 Maternal DM
23 f c.512G>A; p.Trp171* (het) Stop D,C M 1 Maternal DM
24 m c.1339 + 3_6del (het) Splice D, C 1 ND
25 m DEL (het) Deletion TKD§§§ H, M 1 ND
26 m DEL (het) Deletion D, C 1 ND
27 f DEL (het) Deletion D, C H, U, M 1 ND
28 m DEL (het) Deletion D, C 1 No data
29 m c.554C > T; Gln182* (het) Stop D U, M 2 Maternal CRI
30 f c.826C > T; p.Arg276* (het) Stop D, C 1 Maternal Cystic kidney
dysplasia
31 f c.406C >G; p.Gln136Glu (het) Missense D, C 5 ND
32 f DEL (het) Deletion D, c 4 ND
33 f DEL (het) Deletion D, C U, L, M 2 ND
34 m c.443C > T; p.Ser148Leu (het) Missense D, C U, G, L 4 ND
35 f DEL (het) Deletion D, C M 1 De novo
36 m DEL (het) Deletion D, C 1 ND
37 m DEL (het) Deletion D, C 3 De novo
38 m DEL (het) Deletion D, C 1 De novo
39 m c.1045 + 12 T > C (het) Splice D 2 Maternal No anomalies
40 m c.713G> T; p.Trp238Leu (het) Missense D, C L 1 ND
41 f DEL (het) Deletion D, C 1 ND
42 m DEL (het) Deletion D, C 1 ND
43 m DEL (het) Deletion D, C 1 ND
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had undergone transplantation. The median time from initial
diagnosis to ESRD was 7 months (range 1 month–4 years).
At the end of follow-up, CKD I was documented in 36/62
patients (58%), CKD II in 15 (24%), CKD III in 2 (3%), CKD
IVin 4 (7%), and CKDVin 5 patients (8%); the median age of
study patients was 8 years (range 0–19 years; Fig. 2a).
To calculate the annual reduction in GFR loss, we only
included data from patients > 2 years of age—to avoid misin-
terpretation of early creatinine values—with at least two doc-
umented GFR-values. In the total cohort, the mean annual
reduction in GFR was − 1.0 ml/min/1.73 m2 (± 10.3). For
the group of patients with an increase in the number of cysts,
the mean annual reduction in GFR was − 2.8 ml/min/1.73m2/
year (± 13.2) whereas for the group with no increase in cyst
number, the annual GFR development was − 0.33 ml/min/
1.73m2 (± 9.5).
At study onset, we documented for these patients CKD I in
61% (20/33), CKD II in 27% (9/33), CKD III in 3% (1/33),
CKD IV in 9% (3/33), and CKD V in no patient (median age
4 years, range 2–18 years; Fig. 2b).
At the end of follow-up in these 33 patients, we document-
ed: CKD I in 64% (21/33), CKD II in 24% (8/33), CKD III in
no patient, CKD IV in 9% (3/33), and CKD V in 3% (1/33)
(median age 12 years, range 5–19 years; Fig. 2c).
Table 1 (continued)
Patient Gender HNF1B mutation Classification Renal
sonography
Extrarenal
manifestations
CKD Family genetics Family history
44 m DEL (het) Deletion D, C L 1 De novo
45 f c.412 G >A; p.Glu138Lys (het) Missense D, C 2 De novo
46 f DEL (het) Deletion D, C H, U 1 Maternal Gestational
diabetes
47 m DEL (het) Deletion d* 4 ND
48 f c.1492C > T; p.GIn498* (het) Stop D, C U 1 De novo
49 m DEL (het) Deletion D, C 1 ND
50 m c.544 + 1 G > T (het) Splice D 2 ND
51 m DEL (het) Deletion D, C 1 De novo
52 f DEL (het) Deletion D, c 2 ND
53 m DEL (het) Deletion d* U, L, M 2 ND
54 f c.544 + 3_544 + 6delAAGT (het) Splice D, C H, U 1 ND
55 m c.781A>G; p.Arg261Gly (het) Missense D, C U 4 Maternal MODY 5
56 f DEL (het) Deletion D, c U 1 De novo
57 f c.1340-1G >A Splice D, C U, M 1 Maternal ND
58 m DEL (het) Deletion D, C U 1 De novo
59 m DEL (het) Deletion d*, c 1 De novo
60 m c.1340-1G >A Splice c 1 Maternal No anomalies
61 m DEL (het) Deletion D, C 1 De novo
62 m DEL (het) Deletion D, c L, M 1 Maternal Kidney dysplasia;
MODY 5
m male; f, female; C bilateral cysts; c unilateral cysts; D bilateral dysplasia; d unilateral dysplasia; d* unilateral dysplasia + contralateral agenesis; G
genital tract anomalies; H hyperglycemia; U hyperuricemia; L elevated liver enzyme activity; M hypomagnesemia; ND no data. Renal sonography,
extrarenal manifestations, and CKD stage documented at last follow-up. §Variants are annotated in gnomAD and are considered hypomorphic variants in
the context of HNF1B disease. §§ Patient is of consanguineous union. §§§ Patient is affected by a phenotype of tubulointerstitial kidney disease (TKD)
Table 2 Renal function and incidence of extrarenal manifestations, depending on the type of HNF1B mutation
Mutation CKD 1 CKD 2 CKD 3 CKD 4 ESRD Extrarenal manifestations
Deletion (n = 33) 64% (21/33) 21% (7/33) 6% (2/33) 6% (2/33) 3% (1/33) 42% (14/33)
Missense (n = 11) 46% (5/11) 18% (2/11) 0% 18% (2/11) 18% (2/11) 46% (5/11)
Splice/gross insertion (n = 11) 46% (5/11) 36% (4/11) 0% 0% 18% (2/11) 36% (4/11)
Stop (n = 7) 57% (4/7) 43% (3/7) 0% 0% 0% 43% (3/7)
p value > 0.05 between all groups with respect to the type of mutation
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Biochemical data
Hypomagnesemia (Table 3) was detected in 12/50 children
(24%) at a median age of 10 years (mean 8.9 years; range
0–16 years). Magnesium values ranged from 0.5 to
0.6 mmol/l (mean 0.55 mmol/l). 7/29 (24%) patients with
CKD I presented with hypomagnesemia (median age 12;
mean 10; range 0–16 years). In 6/7 patients, hypomagnesemia
was diagnosed at the same time as HNF1B nephropathy, in
one patient 8 years after the initial diagnosis.
Hyperuricemia was detected in 19/52 patients (37%) at a
median age of 1 year (range 0–17 years) and already in 11/32
patients (34%) with CKD I. For all patients, hyperuricemia was
diagnosed at the same time as HNF1B nephropathy. Uric acid
concentrations ranged from 363 to 500 μmol/l (mean
429 μmol/l). No clinical symptoms of gout were present.
Elevated liver enzyme activity was diagnosed in 12/58 pa-
tients (21%) at a median age of 11 years (mean 10.4; range 0–
18 years). For eight of these patients, elevated liver enzymes
were documented at the same time as HNF1B nephropathy at
a median age of 14 years, for four patients with a median lag
time of 10.5 years after initial manifestation of HNF1B
nephropathy.
4/50 patients (8%) experienced recurrent hyperglycemia,
elevated HbA1c levels, or both. The age at manifestation
was 4, 12, and 14 years, respectively, and in one patient, a
neonatal diabetes mellitus (DM) with inhomogeneous pancre-
as texture was diagnosed shortly after birth.
Urogenital abnormalities
One of the 62 patients had hypoplastic testicles; no other uro-
genital abnormalities were documented.
Discussion
The clinical differential diagnosis of HNF1B nephropathy in-
cludes other genetic forms of congenital anomalies of the kid-
neys and urinary tract (CAKUT), ADTKD-UMOD, -MUC1,
87
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Fig. 1 a Prevalence of dysplasia
and cysts in patients with HNF1B
mutation at last follow-up. b Cyst
score over time (n = 94 kidneys
from 47 patients with at least two
renal ultrasound examinations). In
total, 23/94 (24%) kidneys
showed a progress. Patients
defined as progressive with
respect to renal cysts showed a
progress in at least one or both
kidneys. No progress n = 34/47
patients (72%); progress n = 13/
47 patients (28%). We defined a
progress in renal cysts, when
there was a progress in at least one
of the patients’ kidneys
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or -REN but also autosomal dominant polycystic kidney dis-
ease (ADPKD), depending on the ultrasound picture and
extrarenal symptoms. In exceptional cases, ADPKD can man-
ifest itself in very young patients (very early onset [VEO]-
ADPKD) [24]. In most adult cases, the prognosis of
ADPKD is unfavorable, with consistent growth of cysts and
deterioration of renal function. The progression of cyst growth
and renal insufficiency in HNF1B nephropathy has not been
as thoroughly studied so far and was central focus of the here
presented study.
Genotype-phenotype correlation
The present work shows a lack of genotype-phenotype corre-
lations among the various types ofHNF1B gene mutations, as
has been reported previously [11, 14]. One could have expect-
ed gene deletions and loss-of-function mutations with higher
frequency in patients with more severe disease as has been
reported for other kidney disorders [25, 26]. However, this
issue is controversially discussed, and other authors even de-
scribe a more favorable renal outcome in patients with gene
deletions compared to other mutations in HNF1B [27–29].
Possible explanations include a dominant negative effect of
HNF1B non-deletion mutations or the involvement of other
genes located in the deletion interval on chromosome
17q12.3. This interval spans additional 14 genes to HNF1B
and affected patients are also at risk to develop neuropsycho-
logical symptoms. These comprise intellectual disabilities,
learning difficulties, externalization disorders as attention-
deficit hyperactivity disorder and autistic traits with variable
severity [30–32]. Few patients with intellectual disability and
intragenic HNF1B mutations have also been described [32].
To date, however, no studies have systematically called for
expert neuropsychological testing in HNF1B patients, such
as those included in the present study. Follow-up studies will
have to address this important issue strongly impacting the
quality of life of affected individuals.
Like in previous studies, HNF1B mutations were equally
distributed among boys and girls. De novo mutations were
observed in 40% of patients with a preponderance of deletion
mutations (83%). A similar observation was made in [14].
58% CKD I
24% CKD II
3% CKD III
7% CKD IV
8% CKD V
CKD of the total cohort at last follow-up
61%  CKD I
27% CKD II
3% CKD III
9% CKD IV 0% CKD V
CKD at first descripon (paents > 2 years)
64% CKD I
24% CKD II
0 % CKD III
9% CKD IV
3% CKD V
CKD at last follow-up (paents > 2 years)
a
b c
Fig. 2 a Chronic kidney disease
(CKD) of the total cohort at the
end of the observation (n = 62,
mean 8.2 years, median 8 years,
range 0–19 years). b Chronic
kidney disease (CKD) at first
description. Included patients >
2 years to avoid misinterpretation
of early creatinine values with at
least two follow-ups (n = 33,
mean 6.3 years, median 4 years,
range 2–18 years). c Chronic
kidney disease (CKD) at last
description. Included patients >
2 years to avoid misinterpretation
of early creatinine values with at
least two follow-ups (n = 33,
mean 11.2 years, median
12 years, range 7–18 years)
Table 3 Extrarenal manifestations at the end of observation (median
age of the total cohort 8 years, mean 8.2 years)
Extrarenal manifestation Patients % Age at diagnosis
Hypomagnesemia (< 0.65 mmol/l) 12/50 24 10.0 years (median)
Hyperuricemia 19/52 37 1.0 year (median)
Elevated liver enzymes 12/58 21 11.0 years (median)
Hyperglycemia 4/50 8 0, 4, 12, 14 years
Urogenital anomalies 1/62 2 Postnatal
Pediatr Nephrol (2019) 34:1065–1075 1071
Paired segmental duplications along with breakpoints are
most likely involved in the pathogenesis of this recurrent chro-
mosomal microdeletion [33]. One striking observation of the
present study is the high degree (81%) to which HNF1B mu-
tations are inherited through the maternal lineage in familial
cases. Ulinski et al. reported dominant inheritance in 8/17
families; however, no parental data were presented [11]. In a
study involving 42 patients with complete gene deletions,
Heidet et al. identified de novo mutations in 14 of these pa-
tients; for seven patients, there was proven dominant inheri-
tance, with maternal transmission in 6/7 (86%) [14]. A similar
parent-of-origin effect was recently described for non-renal
autosomal disease, e.g., familial early puberty [34] and hered-
itary paraganglioma [35]. Alterations of genomic imprinting
ormaternal imprinting ofmodifying genes were believed to be
involved in these cases. No cascade testing after routine scans
in pregnant women has been performed in our study ruling out
a selection bias. Alternatively, the fertility of adult men with
HNF1B mutations may be reduced. In-depth genetic studies
will be necessary to elucidate these parent-of-origin
mechanisms.
Renal phenotype
Ninety-eight percent of the study patients showed renal dys-
plasia and 90% renal cysts. At a median follow-up of 4 years,
there was no significant increase in the number of renal cysts
in 72% of patients. The mean annual decrease in GFR was −
1.0 ml/min/1.73m2. These findings indicate that HNF1B ne-
phropathy in children is a rather slow-progressive disorder
with respect to cyst development and to loss of kidney func-
tion. These characteristics distinguish the HNF1B phenotype
from the polycystic kidney disease (PKD) spectrum.
Overall, the detection rate of renal cysts in patients with
HNF1B mutations is comparable across the published studies
performed by pediatric nephrologists (84% in [11], 94% in
[13]). In addition, both isolated bilateral hyperechogenic kid-
neys and cystic dysplasia in the antenatal period can be highly
indicative of HNF1B nephropathy [13, 14], and a postnatal
diagnostic clarification is strongly advised for these newborns
including a renal ultrasound in their parents.
Renal function
Among a subset of HNF1B patients, CRF and ESRD seem to
develop when the patients are very young. Five patients rap-
idly developed ESRD with a GFR below 30 ml/min1.73m2
already at an early age. Extrarenal symptoms did not differ
from the rest of the cohort but all were affected by severe
bilateral dysplasia. ESRD is a sequela of severe dysplasia of
both kidneys, independent of the underlying gene mutation.
Presumably, additional genetic factors or modifiers, environ-
mental factors, or epigenetic influences aggravate the disease
in this subset of patients. Similar observations have beenmade
in the subset of young children with VEO-ADPKD [36], for
whom additional genetic variants were identified in PKHD1
or HNF1B and were presumed to act as disease modifiers.
VEO-HNF1B nephropathy requires special attention and
medical care, including early renal replacement therapy.
Non-VEO-HNF1B nephropathy has a more favorable
course, with only a slow decline of renal function over time
during childhood; normal renal function is preserved for many
children. In children with cyst progression, the annual decline
in GFR seems to be pronounced. In previous studies, a normal
GFR (70 ml/min/1.73m2 or higher) was documented in 56%
of pediatric study patients in [11] and in 39% of pediatric
study patients in [13]. During adulthood, loss of renal function
seems to accelerate, as suggested by the results of Faguer et al.
in a series of 27 adult HNF1B patients with a median annual
decrease in GFR of − 2.45 ml/min/1.73m2 [37]. Continuous
follow-up of the pediatric registry with transition into adult-
hoodwill be important for defining this acceleration of decline
in renal function as patients’ age increases. Possible causes
might be related to arterial hypertension, DM, proteinuria, or
dietary salt intake.
Extrarenal manifestations
Hypomagnesemia was diagnosed in 24% of our study patients
but higher rates have been reported in cohorts composed
mostly of older patients. Renal magnesium wasting in
HNF1B disease was first described in [9] in 44% of 21 pa-
tients. Faguer et al. reported hypomagnesemia (Mg <
0.75 mmol/l) in 63% of patients with a median age of 35 years
at last follow-up [37]. In a case series of three adult male
patients, pronounced hypomagnesemia was the first clinical
manifestation of ADTKD-HNF1B [38]. Besides significant
differences in defining hypomagnesemia, the development
of this condition seems to be strongly age-related.
Hyperuricemia was documented in 37% of our study pa-
tients, with an early onset at a median patient age of 1 year.
Only 20% of patients in the study by Bingham et al. [39]
exhibited elevated uric acid levels. Because uric acid concen-
trations are not routinely measured at many pediatric centers,
hyperuricemia may be underdiagnosed. Among patients with
kidney dysplasia, hyperuricemia disproportionate to renal
function highly suggests HNF1B nephropathy as underlying
cause. However, an important differential diagnosis is
ADTKD caused by variants in uromodulin (ADTKD-
UMOD), presenting as familial juvenile hyperuricemic ne-
phropathy and MCKD [40, 41]. The cause of hyperuricemia
in both ADTKD-UMOD and ADTKD-HNF1B is not well
understood, but hyperuricemia seems to be a consequence of
tubulointerstitial dysfunction. Novel experimental studies
have linked HNF1B to mitochondrial energy metabolism in
renal tubular cells [42] providing a possible link to
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transcellular substrate movements. More experimental work
will be necessary for better defining the role ofHNF1B in uric
acid transport and metabolism.
Hyperglycemia, elevated HbA1c levels, or both were
found in only 8% of our patients. Decramer et al. [13] found
DM in 17% of patients; Bingham et al. [39] in 58% (mean age
at diagnosis 25 years); Faguer et al. [37] in 48% (median age
35 years); and Edghill et al. [43] in 48%. These results indicate
that impaired glucose tolerance and DM are rarely observed in
childhood but, even more so than hypomagnesemia, develop
later in the clinical course ofHNF1B disease. However, under
certain circumstances, e.g., after renal transplantation with
concomitant high doses of steroids, tacrolimus, or both, DM
may be unmasked in HNF1B-positive patients [44], requiring
specific treatment and often a change in the immunosuppres-
sive regimen. New-onset diabetes after transplant (NODAT) is
a serious complication compromising renal graft function
[45]. Therefore, screening for HNF1B mutations should be
considered pre-transplant for patients with ESRD caused by
(cystic) kidney dysplasia. In a subgroup of patients, HNF1B
disease first manifests as a disturbance of glucose metabolism
[46]. A recent Norwegian study estimated that the overall
prevalence of monogenic diabetes gene mutations (including
HNF1A, HNF4A, HNF1B, GCK, and INS) in children with
autoantibody-negative DM is very rare with 6.5% [47]. A
study using high-throughput genetic analysis of 4016 patients
with type 2 DM (34% with age at diagnosis of < 40 years)
identified only one HNF1B mutation (age at diagnosis
14 years), whereas mutations in HNF1A and GCK occurred
much more frequently [48]. HNF1B seems to play a minor
role in children (and adults) with isolated autoantibody-
negative DM.
Elevated liver enzyme activity was detected in 21% of
our patients, in 13% in [39], and in 40% in [37]; thus, there
is a high degree of variability among the separate studies.
Results of liver ultrasound seem to be normal in most cases
reported so far; however, a longitudinal follow-up of our
pediatric patients into adulthood will be of interest in eluci-
dating the long-term effects of liver dysfunction in HNF1B
disease.
Genital tract anomalies resulting from Müllerian duct
aplasia and failure of fusion of the Müllerian ducts have re-
peatedly been described in patients with HNF1B mutations
[49, 50]. In our cohort, only one patient was found to have
hypoplastic testicles and no other urogenital abnormalities
were detected. Bingham et al. [39] described uterine
malformations in 14% of female patients and genital tract
malformations in 5% ofmale patients. Edghill et al. [43] found
genital tract anomalies in 9% of patients. Oram et al. identified
mutations inHNF1B in 18% (9/50) of women with combined
uterine and renal abnormalities but in none (0/58) with isolat-
ed malformations of the uterus [51]. Overall, genital tract
malformations are an inconsistent finding. However, when
they are combined with renal abnormalities,HNF1Bmutation
analysis seems advised.
In summary, this report presents the results of a longitudi-
nal dataset from one of the largest pediatric cohorts of patients
with HNF1B nephropathy. With few exceptions, HNF1B ne-
phropathy among children is a rather non-progressive disorder
with respect to cyst development and a slowly progressive
disease with respect to kidney damage. In contrast, VEO-
HNF1B nephropathy is associated with high morbidity rates
and early ESRD. Hyperuricemia is a frequent finding in very
young patients, whereas the prevalence of hypomagnesemia,
elevated liver enzyme activity, and hyperglycemia is higher
among teenagers. A close genotype-phenotype correlation is
lacking; however, we describe a significant parent-of-origin
effect in HNF1B disease, with an 80% preponderance of ma-
ternal inheritance. Future studies employing the combined
efforts of international registries are necessary for identifying
the underlying mechanisms.
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